Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.5149
USD
|
-3.21%
|
|
-18.27%
|
+22.60%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
10.54
|
11.24
|
3.924
|
45.88
|
38.95
|
7.571
|
Enterprise Value (EV)
1 |
9.99
|
8.562
|
4.376
|
55.36
|
28.05
|
14.95
|
P/E ratio
|
-
|
-0.58
x
|
-0.15
x
|
-1.23
x
|
-0.87
x
|
-0.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.28
x
|
3.81
x
|
1.12
x
|
10.9
x
|
9.05
x
|
2.9
x
|
EV / Revenue
|
3.11
x
|
2.91
x
|
1.25
x
|
13.1
x
|
6.51
x
|
5.74
x
|
EV / EBITDA
|
-0.68
x
|
-0.69
x
|
-0.44
x
|
-2.89
x
|
-1.38
x
|
-0.73
x
|
EV / FCF
|
-1.13
x
|
-1.32
x
|
-0.48
x
|
-5.46
x
|
-1.7
x
|
-0.99
x
|
FCF Yield
|
-88.4%
|
-76%
|
-207%
|
-18.3%
|
-58.9%
|
-102%
|
Price to Book
|
-
|
3.4
x
|
1.47
x
|
2.41
x
|
1.13
x
|
1.08
x
|
Nbr of stocks (in thousands)
|
5.64
|
21.6
|
174
|
1,124
|
1,948
|
2,685
|
Reference price
2 |
1,868
|
520.0
|
22.60
|
40.80
|
20.00
|
2.820
|
Announcement Date
|
3/29/18
|
2/27/19
|
3/24/20
|
3/29/21
|
3/30/22
|
3/30/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
3.211
|
2.946
|
3.499
|
4.214
|
4.306
|
2.607
|
EBITDA
1 |
-14.6
|
-12.45
|
-10.05
|
-19.16
|
-20.39
|
-20.58
|
EBIT
1 |
-15.27
|
-13.18
|
-10.97
|
-21.49
|
-23.1
|
-22.22
|
Operating Margin
|
-475.42%
|
-447.35%
|
-313.59%
|
-510.02%
|
-536.51%
|
-852.18%
|
Earnings before Tax (EBT)
1 |
-15.42
|
-13.37
|
-12.45
|
-26.08
|
-34.76
|
-37.28
|
Net income
1 |
-15.42
|
-13.37
|
-12.45
|
-26.21
|
-34.81
|
-37.28
|
Net margin
|
-480.2%
|
-453.72%
|
-355.75%
|
-621.93%
|
-808.3%
|
-1,429.96%
|
EPS
|
-
|
-889.8
|
-154.0
|
-33.18
|
-22.89
|
-15.27
|
Free Cash Flow
1 |
-8.828
|
-6.508
|
-9.075
|
-10.13
|
-16.51
|
-15.18
|
FCF margin
|
-274.92%
|
-220.9%
|
-259.39%
|
-240.43%
|
-383.46%
|
-582.23%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/18
|
2/27/19
|
3/24/20
|
3/29/21
|
3/30/22
|
3/30/23
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
0.8116
|
1.239
|
1.426
|
0.4698
|
0.9672
|
0.4487
|
0.7216
|
0.9134
|
0.7361
|
0.699
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.023
|
-5.087
|
-5.919
|
-5.846
|
-5.272
|
-13.51
|
-9.935
|
-5.07
|
-5.156
|
-3.566
|
Operating Margin
|
-742.13%
|
-410.5%
|
-415.21%
|
-1,244.44%
|
-545.09%
|
-3,011.59%
|
-1,376.81%
|
-555.06%
|
-700.46%
|
-510.09%
|
Earnings before Tax (EBT)
1 |
-7.087
|
-6.057
|
-6.862
|
-6.804
|
-5.84
|
-14.1
|
-10.53
|
-
|
-5.827
|
-4.063
|
Net income
1 |
-7.087
|
-6.057
|
-14.07
|
-6.804
|
-5.84
|
-14.1
|
-10.53
|
-
|
-5.827
|
-4.063
|
Net margin
|
-873.14%
|
-488.79%
|
-987.15%
|
-1,448.37%
|
-603.84%
|
-3,143.23%
|
-1,459.85%
|
-
|
-791.6%
|
-581.24%
|
EPS
2 |
-3.800
|
-3.200
|
-7.000
|
-3.000
|
-2.600
|
-6.000
|
-3.870
|
-
|
-0.9300
|
-0.4600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/12/21
|
11/11/21
|
3/29/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/29/23
|
5/15/23
|
8/10/23
|
11/14/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
0.45
|
9.49
|
-
|
7.38
|
Net Cash position
1 |
0.55
|
2.68
|
-
|
-
|
10.9
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.045
x
|
-0.4952
x
|
-
|
-0.3588
x
|
Free Cash Flow
1 |
-8.83
|
-6.51
|
-9.08
|
-10.1
|
-16.5
|
-15.2
|
ROE (net income / shareholders' equity)
|
-675%
|
-568%
|
-327%
|
-206%
|
-112%
|
-153%
|
ROA (Net income/ Total Assets)
|
-122%
|
-106%
|
-70.8%
|
-44.7%
|
-23.8%
|
-28.5%
|
Assets
1 |
12.61
|
12.63
|
17.58
|
58.7
|
146.3
|
130.9
|
Book Value Per Share
|
-
|
153.0
|
15.40
|
16.90
|
17.70
|
2.610
|
Cash Flow per Share
|
-
|
212.0
|
9.700
|
10.70
|
15.50
|
2.570
|
Capex
1 |
0.28
|
0.15
|
0.03
|
0.13
|
1.98
|
0.59
|
Capex / Sales
|
8.63%
|
5.02%
|
0.91%
|
3.09%
|
46.07%
|
22.66%
|
Announcement Date
|
3/29/18
|
2/27/19
|
3/24/20
|
3/29/21
|
3/30/22
|
3/30/23
|
|
1st Jan change
|
Capi.
|
---|
| +22.60% | 6.5M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|